Tuesday, December 17, 2024 11:12:00 AM
TCI, I think part of the issue is that financial analysts view Amarin as a "going concern". Amarin has stated over and over again that they are going it alone, with very little indication that they are trying to get bought.
So...analysts only look at what Amarin is producing, or what they think they will be producing in the near term, to place a value on it. What any future "potential" means to a buyer is irrelevant to their analysis.
They say "OK, what is the forward-looking revenue...what is the profit margin...what multiple do we place on that...".
It's not REALLY the job of a financial analyst to *speculate* on whether Amarin will get bought or not, especially when Amarin has said very, very little about their desire to be bought.
This is why the stock was bid way up back in 2019. Because everyone assumed Amarin would get bought out at a big multiple because of its "potential", just like most other pre-commercial (or very early stage, as was the case of Amarin with only the MARINE indication up to that point) biotech companies.
And since Amarin doesn't give any forward guidance at all, analysts have very little to go on. So they can only look at what revenue streams are currently in place, and what revenue they see in the next year or two. Outside of Canada, UK, and Spain, we have ZERO revenue (or near-zero), even among the countries that have been approved for years. So what are analysts suppose to glean from that?
Now, if Denner and the board want to flip the script, and start talking about the buyout potential, what the future potential is of Vascepa, what their ultimate plan is, then maybe it will change the perception of the company. But until then, analysts are just going to look at it as a dying company.
FWIW, I think Denner is being VERY deliberate about this. He is not stupid. There's a reason that the company does almost no PR (outside of what is required by the SEC).
When we start hearing a lot from Amarin, the board, Denner, etc., then you know the script is being flipped and they are ready to run.
So...analysts only look at what Amarin is producing, or what they think they will be producing in the near term, to place a value on it. What any future "potential" means to a buyer is irrelevant to their analysis.
They say "OK, what is the forward-looking revenue...what is the profit margin...what multiple do we place on that...".
It's not REALLY the job of a financial analyst to *speculate* on whether Amarin will get bought or not, especially when Amarin has said very, very little about their desire to be bought.
This is why the stock was bid way up back in 2019. Because everyone assumed Amarin would get bought out at a big multiple because of its "potential", just like most other pre-commercial (or very early stage, as was the case of Amarin with only the MARINE indication up to that point) biotech companies.
And since Amarin doesn't give any forward guidance at all, analysts have very little to go on. So they can only look at what revenue streams are currently in place, and what revenue they see in the next year or two. Outside of Canada, UK, and Spain, we have ZERO revenue (or near-zero), even among the countries that have been approved for years. So what are analysts suppose to glean from that?
Now, if Denner and the board want to flip the script, and start talking about the buyout potential, what the future potential is of Vascepa, what their ultimate plan is, then maybe it will change the perception of the company. But until then, analysts are just going to look at it as a dying company.
FWIW, I think Denner is being VERY deliberate about this. He is not stupid. There's a reason that the company does almost no PR (outside of what is required by the SEC).
When we start hearing a lot from Amarin, the board, Denner, etc., then you know the script is being flipped and they are ready to run.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
